PROAIR HFA (albuterol sulfate) by Teva is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 2004.
Drug data last refreshed Just now · AI intelligence enriched 3h ago
PROAIR HFA is a metered-dose inhaler (MDI) containing albuterol sulfate, a beta-2 adrenergic agonist that relaxes bronchial smooth muscle. It is indicated for the treatment of bronchospasm in patients with reversible obstructive airway disease, including asthma. The drug works by stimulating adenyl cyclase to increase cyclic AMP, producing rapid bronchodilation with onset within 5 minutes and peak effect at approximately 1 hour.
As LOE approaches, the brand team will prioritize defensive positioning and cost management rather than growth initiatives, likely resulting in smaller commercial teams and focus on retention.
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on PROAIR HFA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PROAIR HFA offers stable, predictable career opportunities in a mature market where success is measured by market share defense and operational efficiency rather than growth innovation. This is ideal for professionals seeking to deepen expertise in respiratory care, formulary management, and competitive dynamics in a high-volume, price-sensitive segment.